View Older Stories
-
Liquidia Technologies (LQDA) PT Raised to $60 at Jefferies
-
Liquidia Technologies (LQDA) PT Raised to $59 at BTIG
-
Liquidia Corporation (LQDA) Tops Q1 EPS by 15c
-
Liquidia Technologies (LQDA) PT Raised to $55 at H.C. Wainwright
-
Liquidia Technologies (LQDA) PT Raised to $50 at BTIG
-
Liquidia Technologies (LQDA) files mixed shelf
-
BofA on Liquidia (LQDA): 'Management sees limited impact from competitor updates'
-
Raymond James on Liquidia Technologies (LQDA): 'We think the following plots tell the growth story clearly'
-
Liquidia Corporation (LQDA) Misses Q4 EPS by 4c
-
Liquidia Technologies (LQDA) Falls 14%
-
Liquidia Technologies (LQDA) PT Raised to $55 at Jefferies
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
BTIG on Liquidia Technologies (LQDA): 'Next Important Catalyst Most Likely the '327 Trial Outcome'
-
Liquidia Technologies (LQDA) Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
-
Liquidia Technologies (LQDA) spreader of 2500 contracts of January 15 and 30 puts
-
Liquidia Technologies (LQDA) PT Raised to $47 at Raymond James
-
Liquidia Technologies (LQDA) PT Raised to $45 at Jefferies
-
Liquidia Technologies (LQDA) PT Raised to $39 at BofA Securities
-
Liquidia Corporation (LQDA) Tops Q3 EPS by 37c
-
BofA Shuffles Endeavor List Names
-
Jefferies Assumes Liquidia Technologies (LQDA) at Buy
-
Liquidia Technologies (LQDA) PT Raised to $49 at BTIG
-
Liquidia Technologies (LQDA) PT Raised to $41 at Raymond James
-
Liquidia Technologies (LQDA) PT Raised to $31 at Wells Fargo
-
Liquidia Corporation (LQDA) Misses Q2 EPS by 7c
-
Liquidia Technologies (LQDA) Receives $50M from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA
-
Liquidia Technologies (LQDA) call put ratio 1 call to 1 put on 19K contracts
-
Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
-
Raymond James on Liquidia Technologies (LQDA): 'we maintain our positive outlook for the simultaneous Yutrepia launches in PAH and PH-ILD'
-
Liquidia Technologies (LQDA) PT Raised to $45 at BTIG, 'raising our probabilities of success for YUTREPIA in PAH and PH-ILD both to 99% from 95% '
-
Liquidia Technologies (LQDA) PT Raised to $32 at Needham
-
Liquidia Technologies (LQDA) Schedules First Commercial Shipment of YUTREPIA Inhalation Powder
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
Liquidia Technologies (LQDA) PT Raised to $33 at Raymond James
-
Liquidia Technologies (LQDA) PT Raised to $35 at H.C. Wainwright
-
Liquidia Technologies (LQDA) PT Raised to $37 at Scotiabank
-
Liquidia Technologies (LQDA) PT Raised to $23 at Wells Fargo
-
Liquidia Technologies (LQDA) PT Raised to $37 at BTIG
-
Liquidia Technologies (LQDA) PT Raised to $31 at Jefferies
-
Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
Liquidia Technologies (LQDA): U.S. FDA Approves YUTREPIA Inhalation Powder for Patients with PAH and PH-ILD
-
Liquidia Technologies (LQDA) Halted, News Pending
-
Scotiabank Reiterates Sector Outperform Rating on Liquidia Technologies (LQDA)
-
Needham Reiterates Buy Rating on Liquidia Technologies (LQDA), PT $25
-
Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
Oppenheimer Downgrades Liquidia Technologies (LQDA) to Underperform
-
Raymond James on Liquidia (LQDA): 'we see this narrower repackaging of the '793 patent as posing a relatively low risk of becoming a basis for RTO or injunction of the Yutrepia launch'
-
Liquidia Corporation (LQDA) Misses Q1 EPS by 5c

